The projected donor rates for New South Wales calculated by two different methods are contained in table VI. The differences in the rates are due to differences in the sizes of the potential donor poolthat is, the realistic medically suitable potential donor rate. Ifit is assumed that the realistic medically suitable potential donor rate for New South Wales is the same as that in the study hospitals then the actual donor rate would be as high as 18/million population/year. On the other hand, the pool of potential donors implied by the actual donor rate (assuming the same conversion rate as observed in the study hospitals) is smaller than that projected in the first method (51/million population/year v 76/million population/year). It is derived from an actual donor rate of 13/million population/year. The same explanation applies to differences in rates for missed potential donors and potential donors with permission refused for the two methods ofprojection. It is important to note, however, that even if the donor rate is 13/million population/year there is opportunity to increase it by converting missed potential donors to actual donors (an increase of nine donors/million population/year) and by overcoming refusal of permission (an increase of 13 donors/million population/year). If both are overcome the projected rate would be 45/million population/ year. Neither calculation of donor rates takes into account the possibility of potential donors created by interventional ventilation-that is, unrealistic potential donors in whom resuscitation would be solely for the purpose of organ retrieval.
It has been calculated that to satisfy the demand for cadaveric renal transplantation in New South Wales in 1990 and to catch up with the backlog over five years the supply rate needs to be increased 117%; the actual donor rate needs to be increased by 15/million population/year.' Assuming current community attitudes towards retrieval and our low projection of the potential for cadaveric retrieval, conversion of missed potential donors to actual donors would increase supply by about 70% (9/13, table VI). If our high projection of the potential for cadaveric retrieval is assumed then the increase would be about 80% (15/18, table VI).
In conclusion, this study has shown that there is significant unused potential for cadaveric organ retrieval in New South Wales. The two major obstacles are reluctance on the part of medical practitioners to resuscitate potential donors and refusal of permission by the next of kin. This study creates hope that by overcoming these two obstacles, cadaveric organ supply can be increased sufficiently to satisfy demand for all types of organ transplantation. It will be important to find out whether the first obstacle can be overcome by educational intervention among health care providers, and for this the second phase of this study is now in progress.
This work was supported by grants from the New South Wales Department of Health and Sandoz (Australia). Design-Long term foliow up ofa cohort ofpatients with pituitary adenoma and comparison of tumour occurrence with population incidence rates.
Setting-The Royal Marsden Hospital. Subjects-334 patients with pituitary adenoma treated with conservative surgery and radiotherapy (median dose 45 Gy) and followed up for 3760 person years.
Main outcome measures-Second intracranial tumour and systemic malignancy.
Results-Five patients developed a second brain tumour: two had astrocytoma, two meningioma, and one meningeal sarcoma. The cumulative risk of developing a second brain tumour over the first 10 years after treatment was 1-3% (95% confidence interval 0-4% to 3.9%) and over 20 years 1-90/o (0.7% to 5-0%). The relative risk of a second brain tumour compared with the incidence in the normal population was 9*38 (3.05 to 21-89). There was no excess risk of any other type of second primary malignancy.
Conclusions-There is an increased risk of second intracranial tumour in patients with pituitary adenoma treated with surgery and radiotherapy. Although radiation is likely to be the most important factor contributing to the excess risk, further study is required in a cohort of similar patients not receiving radiation.
Introduction
Pituitary adenomas are successfully treated with a range of treatment modalities, which include surgery, radiotherapy, and medical treatment.'7 Radiotherapy is principally employed to reduce the recurrence rate of incompletely excised non-secreting adenomas and in secreting pituitary tumours where hormonal control cannot be achieved with surgery and medical therapy. In these situations radiotherapy combined with limited surgery is successful in controlling pituitary adenoma, resulting in a 90% 10 year progression free survival.' 4 Radiotherapy is relatively safe, with less than 1% BMJ VOLUME 304incidence ofoptic nerve and chiasmal damage, provided that it is delivered accurately and follows well established principles of radiation tolerance. (table II) . Two patients had astrocytoma, two a meningioma, and one a meningeal sarcoma. The diagnosis of second brain tumour was confirmed histologically in four patients (cases 1-4). In case 5 meningioma was diagnosed by computed tomography three days before death (fig 1) . Postmortem examination was not carried out. As far as could be determined the sites of tumour were within the region of entry of anterior or lateral radiation fields, and one tumour arose from within the pituitary fossa (table II) .
The cumulative risk of second brain tumour over the first 10 years after radiotherapy was 1-3% (95% BMJ VOLUME 304 confidence interval 0-4% to 3-9%) and over 20 years 1-9% (0-7% to 5 0%) (fig 2) . astrocytomas were observed compared with 0-25 expected (p=0-031). Compared with the risk of an astrocytoma in the general population the relative risk to patients was therefore 7-92 (95% confidence interval 0 96 to 28 6 1). Three meningeal tumours were observed compared with 0-08 expected (p<0001). Compared with the risk ofa tumour of the meninges in the general population the relative risk to patients was 37-33 (7-69 to 109-08).
There was insufficient information to provide evidence of either an increasing or a decreasing trend in risk by time since radiotherapy (table IV) . However, both astrocytomas occurred relatively soon after treatment (six and seven years respectively) whereas meningeal tumours occurred later. None of the five patients had received bromocriptine.
Nineteen patients developed other second tumours at peripheral sites; nine of these were identified at time of death. The details are shown in table V. No evidence of excess risk of second malignancy at non-cranial sites was seen in these patients (table VI) . However, it is worth noting that three patients developed pancreatic cancer compared with 0-67 expected (p=0.06). When considering mortality from other second tumours no cause specific or overall excess risk was observed. Eleven cancer deaths were observed compared with 15-84 expected (p=0 27).
Discussion
We have found a substantially increased risk of second brain tumours in patients with pituitary adenoma treated with limited surgery and radiotherapy. Many cases of second tumours after treatment of pituitary adenoma, acute lymphatic leukaemia, and other, unrelated brain tumours have been reported, but the number of patients at risk during follow up is not known. The data presented define the overall and relative risks, although small numbers of events have resulted in lack of precision with wide confidence intervals. As a guideline we observed an absolute excess of 4-47 second brain tumours over 3760 patient years, which translates to an excess of 2-4 brain tumours in a group of 100 patients treated in this manner and followed up for 20 years.
As the population under study consisted of patients under close surveillance there was a possibility of bias. We recognise that meningiomas are underreported in the general population since a proportion of tumours are asymptomatic and found only at postmortem examination. It could therefore be argued that the detection ofmeningiomas in this study was due to close observation. There was, however, no policy of routine scanning, and only symptomatic tumours were recorded. The risk of other malignancies, which was comparable to that expected at national rates, also argues against a serious bias. The high relative risk of second tumours cannot therefore be explained by BMJ VOLUME 304 overreporting of cases. Because of the small number of events it is not possible to draw reliable conclusions concerning the effects of possible predisposing factors such as sex, age at the time of treatment, or the secretory status of the tumour.
It is generally assumed that second tumours in the brain are radiation induced. This is based on the recognised increased risk of tumours after low dose irradiation for tinea capitis" and on data from animal experiments.'4 In addition, there are a number ofindividual reported cases ofsecond tumour. Gliomas have been reported in leukaemia survivors,'6 17 and this has been postulated to be due to prophylactic cranial irradiation,'8 19 although there is a possible association between central nervous system tumours and haematopoietic malignancy."' In addition to glial tumours, meningiomas and sarcomas have been described after irradiation,"21 which may be considered akin to sarcomas developing at other sites after therapeutic radiation.2223
Information concerning family history was not routinely collected for this cohort. It is believed, however, from the information contained in the hospital records of the five patients who developed a second brain tumour that none of the five had a family history of cancer or a genetic syndrome which might increase susceptibility to brain tumours. A familial risk of gliomas is known to exist (D F Easton, personal communication) but there is no evidence of any link with pituitary adenoma. However, the possibility of an association such as a genetic or environmental predisposition between pituitary tumours and second brain tumours which is independent of irradiation cannot be excluded. In order to estimate the risk of a second tumour which can be ascribed to radiation the results should be compared with those in a group of control patients with pituitary tumours treated without radiotherapy. As yet such a series of control patients with long term follow up is not available.
Although it is not possible to define the time course of development of second brain tumours from this study, there is a suggestion that astrocytomas occur earlier and meningiomas later. To examine this in more detail we reviewed all available world literature on cases of second intracranial tumour after treatment of pituitary adenoma and craniopharyngioma. Overall 57 cases of second brain tumour, including five patients from this series, had been reported in 45 publications. There were 12 meningiomas, 24 soft tissue sarcomas, three osteogenic sarcomas, and 18 gliomas. Figure 3 shows the cumulative frequency of reported cases of (18 gliomas, 12 meningiomas, 24 sarcomas, includingpatients in this study). Cumulative pertcentage of cases plotted against time since radiotherapy second brain tumours. The median time to detection of glioma was 7-0 years (range 1-22), sarcoma 9 7 years (range 5-27), and meningioma 13-8 years (range 7-33).
We conclude that there is an increased risk ofsecond brain tumour in patients with pituitary adenoma treated with surgery and radiotherapy. Second tumours are not conclusively due to radiation, although this is likely to be the most important contributing factor. The data presented should provide a guideline to the risks oftherapy in patients with pituitary adenoma, but at present they should not be used as a reason to withhold radiotherapy, which remains an effective treatment modality, particularly in patients with residual or recurrent tumour. For a full comparison of different therapeutic approaches it is necessary to know the risks of all the adverse events after surgery alone, and this would include incidence of second tumours.24
